NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-07-23
Reading AVR? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is cautious, given the company's recent struggles and low confidence in management's execution.
The market appears to price in a fragile situation, with an expensive valuation compared to peers. This reflects expectations of potential recovery, but the underlying fundamentals are weak and turbulent.
Fundamentals are likely to remain under pressure due to ongoing losses and a history of earnings misses. Management is focused on advancing the PARADIGM Trial, which could provide some support if successful.
The long-term outlook hinges on the performance of sector bellwethers like ISRG, MDLN, and BDX, as well as potential rate cuts by the Fed. Any shifts in these areas could significantly impact AVR's trajectory.
Over the next 1 to 3 years, AVR's performance will depend on external sector dynamics and internal execution on key trials. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Activating more sites will help get more patients. This is important for running trials.
Confirms:At least three additional sites activated for the PARADIGM Trial in the U.S.
Disproves:No new sites opened in the next quarter. This means there may be delays.
Why it matters: Securing new space is key for Anteris to support its operations and growth.
Confirms:The company has a new office and warehouse in Brooklyn Park, Minnesota.
Disproves:The lease agreement is delayed or canceled. This affects operational plans.
Why it matters: Earnings results show how well the company is doing. This is important for investor trust.
Confirms one read:Earnings report shows revenue growth year over year.
Confirms the other:Earnings report shows revenue decline year over year.
Why it matters: Ending this partnership could free up resources for better projects.
Confirms:A formal announcement says all development work with v2vmedtech has ended.
Disproves:The company may keep working with v2vmedtech or change its decision to stop.
Why it matters: This lease is a key step for Anteris to expand its operations. A successful move can improve efficiency and support growth.
Confirms:The company will use the new office and warehouse space by September 1, 2026.
Disproves:The company delays or cancels the move to the new office and warehouse space.
Why it matters: Hitting this milestone would show strong recruitment momentum and support the trial's progress.
Confirms:U.S. enrolment in the PARADIGM Trial reaches or exceeds 100 patients.
Disproves:U.S. enrolment is under 100 patients. This shows there are problems with recruitment.
Why it matters: CMS updates could affect patient recruitment and site use for the PARADIGM Trial.
Confirms one read:CMS now covers more procedures from the PARADIGM Trial.
Confirms the other:If CMS limits coverage, it will hurt recruitment efforts.
